☰

Alan Fairlamb - Publications

Affiliations: 
University of Dundee, Dundee, Scotland, United Kingdom 
Tree Info Similar researchers PubMed Report error

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Fairlamb AH, Wyllie S. The critical role of mode of action studies in kinetoplastid drug discovery. Frontiers in Drug Discovery. 3. PMID 37600222 DOI: 10.3389/fddsv.2023.1185679  0.302
2021 Paradela LS, Wall RJ, Carvalho S, Chemi G, Corpas-Lopez V, Moynihan E, Bello D, Patterson S, Güther MLS, Fairlamb AH, Ferguson MAJ, Zuccotto F, Martin J, Gilbert IH, Wyllie S. Multiple unbiased approaches identify oxidosqualene cyclase as the molecular target of a promising anti-leishmanial. Cell Chemical Biology. PMID 33691122 DOI: 10.1016/j.chembiol.2021.02.008  0.347
2020 Wall RJ, Carvalho S, Milne R, Bueren-Calabuig JA, Moniz S, Cantizani-Perez J, MacLean L, Kessler A, Cotillo I, Sastry L, Manthri S, Patterson S, Zuccotto F, Thompson S, Martín JJ, ... ... Fairlamb AH, et al. The Q site of cytochrome b is a promiscuous drug target in and . Acs Infectious Diseases. PMID 31967783 DOI: 10.1021/Acsinfecdis.9B00426  0.307
2019 Norcross NR, Wilson C, Baragaña B, Hallyburton I, Osuna-Cabello M, Norval S, Riley J, Fletcher D, Sinden R, Delves M, Ruecker A, Duffy S, Meister S, Antonova-Koch Y, Crespo B, ... ... Fairlamb AH, et al. Substituted aminoacetamides as novel leads for malaria. Chemmedchem. PMID 31188540 DOI: 10.1002/Cmdc.201900329  0.327
2019 Wyllie S, Brand S, Thomas M, De Rycker M, Chung CW, Pena I, Bingham RP, Bueren-Calabuig JA, Cantizani J, Cebrian D, Craggs PD, Ferguson L, Goswami P, Hobrath J, Howe J, ... ... Fairlamb AH, et al. Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. Proceedings of the National Academy of Sciences of the United States of America. PMID 30962368 DOI: 10.1073/Pnas.1820175116  0.301
2019 Baragaña B, Forte B, Choi R, Nakazawa Hewitt S, Bueren-Calabuig JA, Pisco JP, Peet C, Dranow DM, Robinson DA, Jansen C, Norcross NR, Vinayak S, Anderson M, Brooks CF, Cooper CA, ... ... Fairlamb AH, et al. Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. Proceedings of the National Academy of Sciences of the United States of America. PMID 30894487 DOI: 10.1073/Pnas.1814685116  0.328
2018 Corpas-Lopez V, Moniz S, Thomas M, Wall RJ, Torrie LS, Zander-Dinse D, Tinti M, Brand S, Stojanovski L, Manthri S, Hallyburton I, Zuccotto F, Wyatt PG, De Rycker M, Horn D, ... ... Fairlamb AH, et al. Pharmacological validation of N-myristoyltransferase as a drug target in Leishmania donovani. Acs Infectious Diseases. PMID 30380837 DOI: 10.1021/Acsinfecdis.8B00226  0.34
2018 Webster LA, Thomas M, Urbaniak M, Wyllie S, Ong H, Tinti M, Fairlamb AH, Boesche M, Ghidelli-Disse S, Drewes G, Gilbert IH. Development of Chemical Proteomics for the Folateome and Analysis of the Kinetoplastid Folateome. Acs Infectious Diseases. PMID 30264983 DOI: 10.1021/acsinfecdis.8b00097  0.318
2018 Wyllie S, Thomas M, Patterson S, Crouch S, De Rycker M, Lowe R, Gresham S, Urbaniak MD, Otto TD, Stojanovski L, Simeons FRC, Manthri S, MacLean LM, Zuccotto F, Homeyer N, ... ... Fairlamb AH, et al. Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature. PMID 30046105 DOI: 10.1038/S41586-018-0356-Z  0.473
2018 Roberts AJ, Dunne J, Scullion P, Norval S, Fairlamb AH. A role for trypanosomatid aldo-keto reductases in methylglyoxal, prostaglandin and isoprostane metabolism. The Biochemical Journal. PMID 30045874 DOI: 10.1042/BCJ20180232  0.313
2018 Fairlamb AH, Horn D. Melarsoprol Resistance in African Trypanosomiasis. Trends in Parasitology. PMID 29705579 DOI: 10.1016/j.pt.2018.04.002  0.343
2018 Fairlamb AH, Patterson S. Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis. Current Medicinal Chemistry. PMID 29701144 DOI: 10.2174/0929867325666180426164352  0.354
2017 Torrie LS, Brand S, Robinson DA, Ko EJ, Stojanovski L, Simeons FRC, Wyllie S, Thomas J, Ellis L, Osuna-Cabello M, Epemolu O, Nühs A, Riley J, MacLean L, Manthri S, ... ... Fairlamb AH, et al. Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani. Acs Infectious Diseases. PMID 28967262 DOI: 10.1021/acsinfecdis.7b00047  0.303
2016 Wyllie S, Roberts AJ, Norval S, Patterson S, Foth BJ, Berriman M, Read KD, Fairlamb AH. Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania. Plos Pathogens. 12: e1005971. PMID 27812217 DOI: 10.1371/Journal.Ppat.1005971  0.546
2016 Nakazawa Hewitt S, Dranow DM, Horst BG, Abendroth JA, Forte B, Hallyburton I, Jansen C, Baragana B, Choi R, Rivas KL, Hulverson MA, Dumais M, Edwards TE, Lorimer DD, Fairlamb AH, et al. Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase. Acs Infectious Diseases. PMID 27798837 DOI: 10.1021/Acsinfecdis.6B00078  0.316
2016 Dewar S, Sienkiewicz N, Ong HB, Wall RJ, Horn D, Fairlamb AH. The role of folate transport in antifolate drug action in Trypanosoma brucei. The Journal of Biological Chemistry. PMID 27703008 DOI: 10.1074/jbc.M116.750422  0.319
2016 Wyllie S, Foth BJ, Kelner A, Sokolova AY, Berriman M, Fairlamb AH. Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei. The Journal of Antimicrobial Chemotherapy. 71: 625-34. PMID 26581221 DOI: 10.1093/Jac/Dkv376  0.45
2015 Jones DC, Foth BJ, Urbaniak MD, Patterson S, Ong HB, Berriman M, Fairlamb AH. Genomic and Proteomic Studies on the Mode of Action of Oxaboroles against the African Trypanosome. Plos Neglected Tropical Diseases. 9: e0004299. PMID 26684831 DOI: 10.1371/journal.pntd.0004299  0.509
2015 Baragaña B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, Proto WR, Blagborough AM, Meister S, Wirjanata G, Ruecker A, Upton LM, Abraham TS, Almeida MJ, Pradhan A, ... ... Fairlamb AH, et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 522: 315-20. PMID 26085270 DOI: 10.1038/Nature14451  0.362
2015 Shameer S, Logan-Klumpler FJ, Vinson F, Cottret L, Merlet B, Achcar F, Boshart M, Berriman M, Breitling R, Bringaud F, Bütikofer P, Cattanach AM, Bannerman-Chukualim B, Creek DJ, Crouch K, ... ... Fairlamb AH, et al. TrypanoCyc: a community-led biochemical pathways database for Trypanosoma brucei. Nucleic Acids Research. 43: D637-44. PMID 25300491 DOI: 10.1093/Nar/Gku944  0.411
2012 Wyllie S, Patterson S, Fairlamb AH. Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation. Antimicrobial Agents and Chemotherapy. 57: 901-6. PMID 23208716 DOI: 10.1128/AAC.01788-12  0.393
2012 Wyllie S, Patterson S, Stojanovski L, Simeons FR, Norval S, Kime R, Read KD, Fairlamb AH. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Science Translational Medicine. 4: 119re1. PMID 22301556 DOI: 10.1126/scitranslmed.3003326  0.317
2012 Brand S, Cleghorn LA, McElroy SP, Robinson DA, Smith VC, Hallyburton I, Harrison JR, Norcross NR, Spinks D, Bayliss T, Norval S, Stojanovski L, Torrie LS, Frearson JA, Brenk R, ... Fairlamb AH, et al. Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. Journal of Medicinal Chemistry. 55: 140-52. PMID 22148754 DOI: 10.1021/Jm201091T  0.311
2010 Sienkiewicz N, Ong HB, Fairlamb AH. Trypanosoma brucei pteridine reductase 1 is essential for survival in vitro and for virulence in mice. Molecular Microbiology. 77: 658-71. PMID 20545846 DOI: 10.1111/j.1365-2958.2010.07236.x  0.308
2010 Sokolova AY, Wyllie S, Patterson S, Oza SL, Read KD, Fairlamb AH. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrobial Agents and Chemotherapy. 54: 2893-900. PMID 20439607 DOI: 10.1128/AAC.00332-10  0.346
2009 Spinks D, Shanks EJ, Cleghorn LA, McElroy S, Jones D, James D, Fairlamb AH, Frearson JA, Wyatt PG, Gilbert IH. Investigation of trypanothione reductase as a drug target in Trypanosoma brucei. Chemmedchem. 4: 2060-9. PMID 19924760 DOI: 10.1002/cmdc.200900262  0.372
2009 Torrie LS, Wyllie S, Spinks D, Oza SL, Thompson S, Harrison JR, Gilbert IH, Wyatt PG, Fairlamb AH, Frearson JA. Chemical validation of trypanothione synthetase: a potential drug target for human trypanosomiasis. The Journal of Biological Chemistry. 284: 36137-45. PMID 19828449 DOI: 10.1074/jbc.M109.045336  0.332
2009 Richardson JL, Nett IR, Jones DC, Abdille MH, Gilbert IH, Fairlamb AH. Improved tricyclic inhibitors of trypanothione reductase by screening and chemical synthesis. Chemmedchem. 4: 1333-40. PMID 19557801 DOI: 10.1002/cmdc.200900097  0.343
2008 Sienkiewicz N, Jarosławski S, Wyllie S, Fairlamb AH. Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes. Molecular Microbiology. 69: 520-33. PMID 18557814 DOI: 10.1111/j.1365-2958.2008.06305.x  0.305
2007 Caffrey CR, Steverding D, Swenerton RK, Kelly B, Walshe D, Debnath A, Zhou YM, Doyle PS, Fafarman AT, Zorn JA, Land KM, Beauchene J, Schreiber K, Moll H, Ponte-Sucre A, ... ... Fairlamb AH, et al. Bis-acridines as lead antiparasitic agents: structure-activity analysis of a discrete compound library in vitro. Antimicrobial Agents and Chemotherapy. 51: 2164-72. PMID 17371810 DOI: 10.1128/Aac.01418-06  0.336
2006 Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clinical Microbiology Reviews. 19: 111-26. PMID 16418526 DOI: 10.1128/CMR.19.1.111-126.2006  0.338
2005 Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, Bartholomeu DC, Lennard NJ, Caler E, Hamlin NE, Haas B, Böhme U, Hannick L, Aslett MA, Shallom J, Marcello L, ... ... Fairlamb AH, et al. The genome of the African trypanosome Trypanosoma brucei. Science (New York, N.Y.). 309: 416-22. PMID 16020726 DOI: 10.1126/Science.1112642  0.48
2004 Wyllie S, Cunningham ML, Fairlamb AH. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani Journal of Biological Chemistry. 279: 39925-39932. PMID 15252045 DOI: 10.1074/jbc.M405635200  0.348
2002 Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, ... ... Fairlamb AH, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 419: 498-511. PMID 12368864 DOI: 10.1038/Nature01097  0.478
2002 Fairlamb AH. Metabolic pathway analysis in trypanosomes and malaria parasites. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 357: 101-7. PMID 11839187 DOI: 10.1098/rstb.2001.1040  0.392
Show low-probability matches.